Pulmonary hypertension complicating sarcoidosis

Area of Science:

• Pulmonary Medicine
• Cardiology
• Rheumatology

Background:

• Pulmonary hypertension (PH) is a known complication of sarcoidosis, with prevalence varying by disease stage.
• Approximately 6% of sarcoidosis patients develop PH, influenced by factors beyond hypoxemia.
• Sarcoidosis-associated PH (SAPH) mechanisms are multifactorial, including vasculopathy, vasoreactivity, extrinsic compression, and portal hypertension.

Purpose of the Study:

• To summarize the current understanding of SAPH, its mechanisms, and clinical implications.
• To highlight the diagnostic challenges and prognostic significance of PH in sarcoidosis.
• To review current management strategies and identify areas for future research.

Main Methods:

• Review of existing literature on sarcoidosis and pulmonary hypertension.
• Analysis of reported prevalence rates and etiological factors.
• Discussion of diagnostic approaches, including right heart catheterization.
• Evaluation of current and potential therapeutic interventions.

Main Results:

• SAPH mechanisms are complex, involving specific vasculopathy, particularly affecting the venous side, and potentially leading to pulmonary veno-occlusive disease.
• "Out of proportion" PH (mean PAP >35-40mmHg) is observed in a subset of patients.
• PH significantly worsens prognosis in sarcoidosis, increasing morbidity and mortality.
• Current management focuses on supportive care, lung transplantation, and limited use of corticosteroids.
• Efficacy of pulmonary arterial hypertension agents in SAPH remains uncertain.

Conclusions:

• SAPH is a severe complication with multifactorial origins and poor prognosis.
• Accurate diagnosis and risk stratification are essential.
• Further research, including controlled trials, is needed to clarify treatment efficacy, particularly for disproportionate PH.